$ELOX
Eloxx Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022029339 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.262M $2.645M $3.054M
YoY Change -55.07% -64.04% -29.63%
% of Gross Profit
Research & Development $4.880M $7.651M $7.899M
YoY Change -6.33% 34.13% 94.08%
% of Gross Profit
Depreciation & Amortization $23.00K $22.00K $21.00K
YoY Change -23.33% -45.0% 31.25%
% of Gross Profit
Operating Expenses $7.142M $10.30M $10.95M
YoY Change -30.29% -71.18% 30.18%
Operating Profit -$7.142M -$10.30M -$10.95M
YoY Change -30.29% -71.18% 30.18%
Interest Expense -$366.0K -$322.0K -$667.0K
YoY Change 103.33% -2.13% 138.21%
% of Operating Profit
Other Income/Expense, Net -$366.0K -$322.0K -$667.0K
YoY Change -201.67% -2.13% 138.21%
Pretax Income -$7.508M -$10.62M -$11.62M
YoY Change -24.05% -70.55% 33.72%
Income Tax
% Of Pretax Income
Net Earnings -$7.508M -$10.62M -$11.62M
YoY Change -24.05% -70.55% 33.66%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.12 -$5.36
Diluted Earnings Per Share -$0.09 -$0.12 -$134.1K
COMMON SHARES
Basic Shares Outstanding 86.66M 86.65M 2.166M
Diluted Shares Outstanding 86.66M 86.65M 2.166M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.55M $30.05M $39.77M
YoY Change -53.17% -47.04% 117.91%
Cash & Equivalents $24.55M $30.05M $39.77M
Short-Term Investments
Other Short-Term Assets $1.117M $1.544M $2.379M
YoY Change 0.63% -15.4% 39.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.67M $31.59M $42.15M
YoY Change -52.05% -46.05% 111.16%
LONG-TERM ASSETS
Property, Plant & Equipment $215.0K $190.0K $206.0K
YoY Change -4.02% 2.7% 76.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.208M $1.349M $1.471M
YoY Change -34.38% -34.23% 258.78%
TOTAL ASSETS
Total Short-Term Assets $25.67M $31.59M $42.15M
Total Long-Term Assets $1.208M $1.349M $1.471M
Total Assets $26.88M $32.94M $43.62M
YoY Change -51.47% -45.65% 114.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.595M $1.934M $2.903M
YoY Change -36.43% -4.45% 492.45%
Accrued Expenses $4.518M $4.870M $4.631M
YoY Change 73.04% 47.49% 58.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.530M $1.125M
YoY Change -80.21%
Total Short-Term Liabilities $21.68M $19.50M $19.17M
YoY Change 127.97% 28.23% 51.1%
LONG-TERM LIABILITIES
Long-Term Debt $9.863M $11.13M $12.12M
YoY Change -17.19% 205.99% 146.69%
Other Long-Term Liabilities $318.0K $496.0K $638.0K
YoY Change -67.01% -55.71% 6280.0%
Total Long-Term Liabilities $9.863M $11.13M $12.12M
YoY Change -17.19% 205.99% 146.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.68M $19.50M $19.17M
Total Long-Term Liabilities $9.863M $11.13M $12.12M
Total Liabilities $31.86M $31.13M $31.93M
YoY Change 42.33% 65.17% 81.23%
SHAREHOLDERS EQUITY
Retained Earnings -$268.1M -$260.6M -$249.9M
YoY Change 18.52% 20.48% 38.6%
Common Stock $265.3M $264.6M $263.8M
YoY Change 65201.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.982M $1.812M $11.69M
YoY Change
Total Liabilities & Shareholders Equity $26.88M $32.94M $43.62M
YoY Change -51.47% -45.65% 114.13%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$7.508M -$10.62M -$11.62M
YoY Change -24.05% -70.55% 33.66%
Depreciation, Depletion And Amortization $23.00K $22.00K $21.00K
YoY Change -23.33% -45.0% 31.25%
Cash From Operating Activities -$6.946M -$9.747M -$9.491M
YoY Change -8.46% -0.46% 23.5%
INVESTING ACTIVITIES
Capital Expenditures -$48.00K -$7.000K $11.00K
YoY Change -30.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$48.00K -$7.000K -$11.00K
YoY Change -30.43% -100.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.500M 0.000 7.000M
YoY Change -55.29% -100.0% 454.68%
NET CHANGE
Cash From Operating Activities -6.946M -9.747M -9.491M
Cash From Investing Activities -48.00K -7.000K -11.00K
Cash From Financing Activities 1.500M 0.000 7.000M
Net Change In Cash -5.494M -9.754M -2.502M
YoY Change 27.71% -125.21% -61.05%
FREE CASH FLOW
Cash From Operating Activities -$6.946M -$9.747M -$9.491M
Capital Expenditures -$48.00K -$7.000K $11.00K
Free Cash Flow -$6.898M -$9.740M -$9.502M
YoY Change -8.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Central Index Key
EntityCentralIndexKey
0001035354
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M15D
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31326
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42268000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
31592000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
190000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1159000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1443000
CY2022Q2 us-gaap Assets
Assets
32941000
CY2021Q4 us-gaap Assets
Assets
45139000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4196000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1125000
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
166000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1812000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7355000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
22670000
us-gaap Operating Expenses
OperatingExpenses
21249000
us-gaap Operating Expenses
OperatingExpenses
44143000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35729000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-989000
us-gaap Net Income Loss
NetIncomeLoss
-22238000
us-gaap Net Income Loss
NetIncomeLoss
-44752000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86654120
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86654120
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66389865
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66389865
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86652587
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86652587
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53357401
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53357401
us-gaap Profit Loss
ProfitLoss
-22238000
us-gaap Profit Loss
ProfitLoss
-44752000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
22670000
us-gaap Share Based Compensation
ShareBasedCompensation
1666000
us-gaap Share Based Compensation
ShareBasedCompensation
5343000
us-gaap Depreciation
Depreciation
44000
us-gaap Depreciation
Depreciation
56000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
263000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
284000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
423000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
258000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
246000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30311000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
208000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56980000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-84000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
166000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
368000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
84000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
555000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-75000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
674000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
69000
us-gaap Stock Issued1
StockIssued1
22335000
us-gaap Interest Paid Net
InterestPaidNet
620000
us-gaap Interest Paid Net
InterestPaidNet
273000
us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
1003000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-279000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-417000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22384000
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-4000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19238000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17482000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2145000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2145000
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
7000000
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
2606000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47718000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2500000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
237000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47593000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12256000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32256000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42567000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24724000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30311000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56980000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30048000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56734000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
922000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11620000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11686000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
744000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1812000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10230000
CY2021Q1 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-94000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1308000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8694000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2750000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2021Q2 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-143000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4035000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
22335000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47718000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36058000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
40643000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-260600000
CY2022Q2 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
30000000.0
CY2022Q2 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3814000
CY2021Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1849000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
468000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1615000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
268000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
489000
CY2022Q2 elox Accrued Interest On Debt
AccruedInterestOnDebt
111000
CY2022Q2 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
164000
CY2021Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
413000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
704000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
123000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
413000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
377000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1281000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
913000
CY2021Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
102000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
209000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
338000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
387000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
148000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
171000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
190000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
216000
CY2022Q2 us-gaap Depreciation
Depreciation
22000
CY2021Q2 us-gaap Depreciation
Depreciation
40000
us-gaap Depreciation
Depreciation
44000
us-gaap Depreciation
Depreciation
56000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
141000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4870000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4196000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4204000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6101000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2195000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12500000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1065000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
11435000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1125000
CY2022Q2 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-819000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11129000
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
323892
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
323892
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P1Y2M26D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8904444
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.24
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
254223
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3269497
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1645501
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.96
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10528440
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.17
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
254223
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2916545
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.57
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
254223
us-gaap Interest Expense Other
InterestExpenseOther
579000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
11000
us-gaap Interest And Other Income
InterestAndOtherIncome
25000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
744000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4035000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1666000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5343000
elox Fair Value Assets Transfers Between Level2 And Level3 Description
FairValueAssetsTransfersBetweenLevel2AndLevel3Description
Company did not have any transfers of financial assets between levels
elox Fair Value Of Unobservable Assumptions Period
FairValueOfUnobservableAssumptionsPeriod
P3Y
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
475000
CY2021Q2 us-gaap Interest Expense Other
InterestExpenseOther
319000
us-gaap Interest Expense Other
InterestExpenseOther
879000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
38000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
31000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30000
CY2022Q2 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-104000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
166000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-322000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-329000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-989000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-609000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36058000
us-gaap Net Income Loss
NetIncomeLoss
-22238000
us-gaap Net Income Loss
NetIncomeLoss
-44752000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86654120
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86654120
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66389865
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66389865
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86652587
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86652587
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53357401
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53357401
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10852332
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8613792
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity Registrant Name
EntityRegistrantName
ELOXX PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Arsenal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
577-5300
dei Trading Symbol
TradingSymbol
ELOX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
299000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9777000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86656221
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30048000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
263000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1281000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
913000
CY2021Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
3723000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
657000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9955000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11996000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
804000
CY2021Q4 us-gaap Liabilities
Liabilities
22755000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1934000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4870000
CY2022Q2 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
10723000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
43480000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
216000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1379000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
686000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19504000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11129000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
496000
CY2022Q2 us-gaap Liabilities
Liabilities
31129000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87077587
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86656221
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
871000
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
421366
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2190000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263692000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-260561000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87071324
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86649958
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
871000
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
421366
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2190000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
262026000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238323000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22384000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45139000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5704000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15550000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2645000
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
22670000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
10296000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44143000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5699000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11696000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
35729000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21249000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-322000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-329000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-609000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36058000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32941000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7651000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10296000

Files In Submission

Name View Source Status
0001564590-22-029339-index-headers.html Edgar Link pending
0001564590-22-029339-index.html Edgar Link pending
0001564590-22-029339.txt Edgar Link pending
0001564590-22-029339-xbrl.zip Edgar Link pending
elox-10q_20220630.htm Edgar Link pending
elox-20220630.xsd Edgar Link pending
elox-ex311_9.htm Edgar Link pending
elox-ex312_7.htm Edgar Link pending
elox-ex321_8.htm Edgar Link pending
elox-ex322_6.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
elox-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elox-20220630_pre.xml Edgar Link unprocessable
elox-20220630_def.xml Edgar Link unprocessable
elox-10q_20220630_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
elox-20220630_cal.xml Edgar Link unprocessable